Now showing items 1-2 of 2

    • Aberrant regulation of the GSK-3b/NRF2 axis unveils a novel therapy for adrenoleukodystrophy 

      Ranea-Robles, Pablo; Launay, Nathalie; Ruiz, Montserrat; Calingasan, Noel Ylagan; Dumont, Magali; Naudí i Farré, Alba; Portero Otín, Manuel; Pamplona Gras, Reinald; Ferrer, Isidre; Beal, M. Flint; Fourcade, Stéphane; Pujol, Aurora (Wiley Open Access, 2018)
      The nuclear factor erythroid 2-like 2 (NRF2) is the master regulator of endogenous antioxidant responses. Oxidative damage is a shared and early-appearing feature in X-linked adrenoleukodystrophy (X-ALD) patients and ...
    • Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy 

      Morató, Laia; Galino, Jorge; Ruiz, Montserrat; Calingasan, Noel Ylagan; Starkov, Anatoly A.; Dumont, Magali; Naudí i Farré, Alba; Martínez, Juan José; Aubourg, Patrick; Portero Otín, Manuel; Pamplona Gras, Reinald; Galea, Elena; Flint Beal, M.; Ferrer, Isidre; Fourcade, Stéphane; Pujol, Aurora (Oxford Journals, 2013)
      X-linked adrenoleukodystrophy is a neurometabolic disorder caused by inactivation of the peroxisomal ABCD1 transporter of very long-chain fatty acids. In mice, ABCD1 loss causes late onset axonal degeneration in the spinal ...